Medpace Clinical Pharmacology Unit (CPU) focuses on Phase I and IIa confined/controlled pharmacokinetic and pharmacodynamic studies utilizing special patient populations, with first-in-man capability.
For example, some of the PK studies Medpace can conduct are:
- Single ascending dose.
- Multiple ascending dose.
- Drug-drug interaction.
- Food interaction.
- Special populations: hepatic / renal impairment; gender effect; age effect.
- PK/PD Modeling.
- Population pharmacokinetics.
Equipped with state-of-the-art tools and technology, the CPU conducts studies including:
- 24-hour continuous glucose monitoring (CGM) for up to three days.
- Continuous blood pressure monitoring and wireless telemetry systems for continuous electrocardiogram (ECG) monitoring for proof-of-concept studies (POC).
- First-in-man studies.
- Thorough QTc studies.
Medpace Clinical Pharmacology also executes extensive pharmacokinetic profiles for absorption, distribution, metabolism, excretion (ADME), bioequivalence (BE), and drug interaction studies in human subjects. Special population research, including renal impairment studies are also provided.
Want to learn more? Contact the Medpace location nearest you.